Novartis AG (NVS) Given Consensus Rating of “Hold” by Analysts

Shares of Novartis AG (NYSE:NVS) have been given a consensus rating of “Hold” by the nineteen brokerages that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, ten have issued a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $83.19.

A number of equities research analysts recently commented on the company. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis in a research report on Tuesday, September 26th. Barclays downgraded Novartis from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Leerink Swann upped their price objective on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Zacks Investment Research downgraded Novartis from a “buy” rating to a “hold” rating in a research report on Thursday, September 21st. Finally, Bank of America downgraded Novartis from a “neutral” rating to an “underperform” rating in a research report on Wednesday, December 6th.

Several hedge funds and other institutional investors have recently modified their holdings of NVS. WFG Advisors LP grew its stake in Novartis by 38.1% in the second quarter. WFG Advisors LP now owns 1,221 shares of the company’s stock worth $102,000 after purchasing an additional 337 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new position in Novartis in the third quarter worth approximately $106,000. Cable Hill Partners LLC grew its stake in Novartis by 588.8% in the third quarter. Cable Hill Partners LLC now owns 1,295 shares of the company’s stock worth $112,000 after purchasing an additional 1,107 shares in the last quarter. Harding Loevner LP bought a new position in Novartis in the second quarter worth approximately $146,000. Finally, Mosaic Family Wealth LLC grew its stake in Novartis by 6.1% in the second quarter. Mosaic Family Wealth LLC now owns 2,144 shares of the company’s stock worth $179,000 after purchasing an additional 123 shares in the last quarter. Hedge funds and other institutional investors own 10.85% of the company’s stock.

Novartis (NVS) traded down $0.54 during midday trading on Tuesday, hitting $82.95. The stock had a trading volume of 803,700 shares, compared to its average volume of 2,215,349. The company has a market capitalization of $196,226.09, a price-to-earnings ratio of 29.52, a price-to-earnings-growth ratio of 2.63 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. Novartis has a 1 year low of $69.53 and a 1 year high of $86.90.

Novartis (NYSE:NVS) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.25 by $0.04. The firm had revenue of $12.41 billion during the quarter, compared to analyst estimates of $12.21 billion. Novartis had a return on equity of 15.77% and a net margin of 13.73%. The business’s quarterly revenue was up 2.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.23 earnings per share. sell-side analysts forecast that Novartis will post 4.76 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Novartis AG (NVS) Given Consensus Rating of “Hold” by Analysts” was first posted by Week Herald and is the sole property of of Week Herald. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this article can be viewed at https://weekherald.com/2017/12/26/novartis-ag-nvs-given-consensus-rating-of-hold-by-analysts-2.html.

About Novartis

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply